In recent years the future position of clinical endocrinology has been
extensively discussed by Western European endocrine societies. Clinical
endocrinology seems to suffer from being too intellectual, generating too
little income, and lacking too few spectacular interventions. In this
manuscript we describe 'the endocrine patient' of the past, the present,
and the future. Complete therapeutic breakthroughs resulting in 'cure' are
compared with 'halfway technologies' which help in creating the
(life-long) chronic endocrine patient. The potential use of molecular
diagnostics in optimalizing hormone replacement therapy is discussed.
Clinical endocrinology is at risk of developing into a subspecialty where
life-style drugs created for new diseases or conditions are offered, but
also actively pursued by otherwise healthy individuals (e.g. in normal
short stature, regulation of appetite, body composition, sexuality,
reproduction and aging). The potential opportunities and risks for
clinical endocrinology in creating 'the endocrine patient' of the future
are discussed